Dapagliflozin to prevent atrial fibrillation recurrence after cardioversion

This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.

This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.

This study tests whether a daily medication called dapagliflozin (usually used for diabetes) can improve the success of rhythm control (treatments that bring your heartbeat back to normal) in people with recent atrial fibrillation. If you join, you would receive either the study drug or a placebo along with standard care.

This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.

This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.

This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.